ERYTHROMYCIN/ZINC ACETATE, ZINERYT

For cutaneous use. Apply twice daily over the whole of the affected area for a period of 10 to 12 weeks.

Tabulated list of adverse reactions System Organ Class Rare (³1/10,000 to<1/1000) Very rare (<1/10,000) Not known (cannot be estimated from the available data) Not known (cannot be estimated from the available data) Immune system disorders Hypersensitivity Skin and subcutaneous tissue disorders Pruritus Erythema Skin irritation Skin burning sensation Dry skin Skin exfoliation Acute generalised exanthematous pustulosis (AGEP)* *Reported after systemic administration Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported after systemic administration. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted.

Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued. Cross resistance may occur with other antibiotics of the macrolide group and also with lincomycin and clindamycin.

Contact with the eyes or the mucous membranes of the nose and mouth should be avoided.

1.